Home - Products - Chromatin/Epigenetic - Epigenetic Reader Domain - 2-methyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-4-one

2-methyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-4-one

CAS No. 96680-77-2

2-methyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-4-one( —— )

Catalog No. M28385 CAS No. 96680-77-2

2-methyl-2,3-dihydro-1,5-benzothiazepin-4(5H)-one is ligand of CBP.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
10MG 29 In Stock
25MG 51 In Stock
50MG 75 In Stock
100MG 112 In Stock
200MG 168 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    2-methyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-4-one
  • Note
    Research use only, not for human use.
  • Brief Description
    2-methyl-2,3-dihydro-1,5-benzothiazepin-4(5H)-one is ligand of CBP.
  • Description
    2-methyl-2,3-dihydro-1,5-benzothiazepin-4(5H)-one is ligand of CBP.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Chromatin/Epigenetic
  • Target
    Epigenetic Reader Domain
  • Recptor
    Human Endogenous Metabolite|GPR109B|AhR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    96680-77-2
  • Formula Weight
    193.26
  • Molecular Formula
    C10H11NOS
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    CC1CC(=O)Nc2ccccc2S1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Wang XD, et al. A method for the determination of D-kynurenine in biological tissues. Anal Bioanal Chem. 2013 Dec;405(30):9747-54.
molnova catalog
related products
  • CCT077791

    CCT077791 is a potent inhibitor of p300 and PCAF histone acetyltransferase activity for cancer research.

  • CBP/EP300-IN-1

    CBP/EP300-IN-1 is a CBP/EP300 bromodomain inhibitor.

  • PBRM1-BD2-IN-7

    PBRM1-BD2-IN-7, a selective and cell-active inhibitor targeting the polybromo-1 (PBRM1) bromodomain, demonstrates inhibitory efficacy against PBRM1-BD2 with an IC50 value of 0.29 μM.